1. Home
  2. NCL vs INDP Comparison

NCL vs INDP Comparison

Compare NCL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northann Corp.

NCL

Northann Corp.

HOLD

Current Price

$0.17

Market Cap

3.9M

Sector

N/A

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.05

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCL
INDP
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.5M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
NCL
INDP
Price
$0.17
$2.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
374.4K
23.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
51.43
12.02
EPS
N/A
N/A
Revenue
$15,349,854.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.86
N/A
52 Week Low
$0.10
$0.27
52 Week High
$1.47
$13.24

Technical Indicators

Market Signals
Indicator
NCL
INDP
Relative Strength Index (RSI) 42.71 48.88
Support Level $0.16 $1.92
Resistance Level $0.19 $3.19
Average True Range (ATR) 0.02 0.17
MACD 0.00 0.06
Stochastic Oscillator 22.87 76.80

Price Performance

Historical Comparison
NCL
INDP

About NCL Northann Corp.

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: